Molecular Formula | C24H35ClO9 |
Molar Mass | 502.9823 |
Melting Point | 74 - 78°C |
Solubility | 10 mM in DMSO |
Appearance | Solid |
Color | White to Off-White |
Storage Condition | -20°C Freezer |
Use | Use dapagliflozin monohydrate is an SGLT2 inhibitor that can be used to treat diabetes |
Abstract:
Dapagliflozin is one of the representative drugs of SGLT2 inhibitor, which was officially approved by China Food and Drug Administration (CFDA) in 2017, became the first marketed SGLT2 inhibitor in China. It is simple and convenient to take orally and can be used alone or in combination. In addition to reducing Hb A1c, it can also reduce body weight and blood pressure. It is a promising new hypoglycemic drug. As a new drug with a short time to market, there is still a lack of a large number of clinical data to confirm its safety and effectiveness. Therefore, in the clinic, Dapagliflozin is only used as a first-line hypoglycemic drug (such as metformin) alternatives, especially when conventional medical therapy is not available.
Key words:
type 2 diabetes mellitus; Dapagliflozin; Progression; clinical application
DOI:
10.14053/j.cnki.ppcr.201711030
cited:
year:
2017
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.988 ml | 9.941 ml | 19.881 ml |
5 mM | 0.398 ml | 1.988 ml | 3.976 ml |
10 mM | 0.199 ml | 0.994 ml | 1.988 ml |
5 mM | 0.04 ml | 0.199 ml | 0.398 ml |
Professor Parikh, from AstraZeneca, reported on a meta-analysis at the 75th American ADA Scientific Sessions to explore whether proteinuria as a marker of diabetic nephropathy and its impact on dapagliflozin (DAPA) efficacy.
Key words:
diabetic nephropathy AstraZeneca HbA1c meta-analysis randomised control clinical trials proteinuria ADA
year:
2015